Vaccine therapies for Non-Hodgkin’s Lymphoma

Current Treatment Options in Oncology

Volumn 3, Issue 4, 2002, Pages 307-315

  Timmerman, John M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dendritic Cell Vaccine; Follicular Lymphoma; Main Drug Interaction; Mantle Cell Lymphoma; Vaccine Therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; MONOCLONAL ANTIBODY;

CLINICAL TRIAL; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY; NONHODGKIN LYMPHOMA; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; LYMPHOMA, NON-HODGKIN;

EID: 0036673919     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-002-0030-3     Document Type: Article

References (14)

1. Timmerman JM, Levy RL: The history of the development of vaccines for lymphoma. Clin Lymphoma 2000, 1:129–139. DOI: 10.3816/CLM.2000.n.011
2. McLaughlin P, Grillo-Lopez AJ, Link BK, et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825–2833.
3. Borrello I, Sotomayor EM, Rattis FM, et al.: Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. Blood 2000, 95:3011–3019.
4. Wierda WG, Cantwell MJ, Woods SJ, et al.: CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 2000, 96:2917–2924.
5. Janetzki S, Palla D, Rosenhauer V, et al.: Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study. Int J Cancer 2000, 88:232–238. DOI: 10.1002/1097-0215(20001015)88:2<232::AID-IJC14>3.0.CO;2-8
6. Kwak LW, Campbell MJ, Czerwinski DK, et al.: Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 1992, 327:1209–1215. DOI: 10.1056/NEJM199210223271705
7. Hsu FJ, Benike C, Fagnoni F, et al.: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996, 2:52–58. DOI: 10.1038/nm0196-52
8. Timmerman JM, Czerwinski DK, Davis TA, et al.: Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002, 99:1517–1526. DOI: 10.1182/blood.V99.5.1517
9. Timmerman JM, Levy R: Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 1999, 50:507–529. DOI: 10.1146/annurev.med.50.1.507
10. Bendandi M, Gocke CD, Kobrin CB, et al.: Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colonystimulating factor against lymphoma. Nat Med 1999, 5:1171–1177. DOI: 10.1038/13928
11. Timmerman JM, Czerwinski D, Taid B, et al.: A phase I/II trial to evaluate the immunogenicity of recombinant idiotype protein vaccines for the treatment of non-Hodgkin’s lymphoma (NHL). Blood 2000, 96:578a.
12. Leukine [package insert]. Seattle, WA: Immunex. www.immunex.com.
13. Zhu D, Rice J, Savelyeva N, Stevenson FK: DNA fusion vaccines against B-cell tumors. Trends Mol Med 2001, 7:566–572. DOI: 10.1016/S1471-4914(01)02126-8
14. Timmerman JM, Singh G, Hermanson G, et al.: A phase I/II study of DNA idiotype vaccination for B-cell lymphoma. 92nd Annual Meeting of the American Association for Cancer Research. New Orleans, LA: March 24-28, 2001. Abstract 3759.